Is it real or science fiction to dream of being able to treat… getting old? In this episode, we discuss with Dr. Thomas Rando from Stanford (who directs the Glenn Center for the Biology of Aging), Kristen Fortney, CEO of BioAge, and a16z’s general partner Vijay Pande where we are in the field of “geroscience” — the idea of studying, well, aging itself, and aging as the root risk for all aging related disease. Far from science fiction, recent discoveries have given us a whole crop of promising breakthroughs to treat aging, such as parabiosis (young blood infused into old blood), senolytics, and rapamycin, and more.

What we’re beginning to see is a fundamental shift away from the idea of searching for immortality and towards the idea of increasing "health span” — where prevention means much more than eating healthier or exercising more. Are we moving from Dx to Rx to — perhaps Px? What will it look like when anti-aging therapies actually begin to be delivered to us: small molecule or protein or an antibody — or something else entirely? A pill or a blood transfusion treatment? A vaccine for aging?

And finally, what has to change — conceptually, scientifically, logistically, in regulation -- to get these therapies into the hands of all?

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

a16z Podcast: The Science Of Extending Life

The a16z Show